INTRODUCTION
Cancer treatments have been transformed with recent advances in cancer immunotherapy.1
As monotherapies, these agents have demonstrated clinical activity across many tumor
types. Further advances in the effectiveness of cancer immunotherapies will require
targeting antitumor immune response at multiple levels, which may be accomplished
through combination approaches. This review discusses the current landscape of cancer
immunotherapy, combinations in clinical development, strategies for dose selection
and trial design, and clinical pharmacology and regulatory considerations.
HISTORY OF CANCER IMMUNOTHERAPY AND APPROVED THERAPIES
Cancer kills over 8 million people worldwide every year and the number of diagnosed
cases is expected to almost double in the next two decades.2 Surgery, radiation, chemotherapy,
and targeted agents are commonly used to treat these patients, but many patients either
relapse or are refractory to treatment. In addition, patients and physicians must
manage a variety of side effects that have a significant impact on patients’ quality
of life, which limits the use of these agents.
It is well established that cancer cells can be recognized by the immune system, and
it is hypothesized that the defeat of the immune surveillance system underlies the
development of malignancies and the lack or loss of response to treatment.3, 4 Under
normal circumstances, a functioning immune surveillance system will recognize and
eliminate transformed cells. Ironically, this Darwinian process ultimately results
in the selection of tumor cells resistant to processing by the immune system through
loss of antigenicity, defects in antigen presentation, and decreased immunogenicity
(e.g., through upregulation of PD1, a negative regulator of the immune system).5 Immune
escape is also accomplished by the alteration of the tumor microenvironment,5 whereby
tumor cells recruit immune‐suppressive cells to promote conditions for their survival.
Immuno‐oncology approaches attempt to restore the immune surveillance system and activate
the patient's immune system to fight their cancer. These approaches have garnered
significant attention and are projected to be the new standard of care for diverse
tumor types. Indeed, the clinical data of recent regulatory approvals of immunotherapy
treatments including blinatumomab (BLINCYTO), ipilimumab (Yervoy), nivolumab (Opdivo),
and pembrolizumab (Keytruda) across multiple cancer types demonstrate the clinical
feasibility of this approach.
The promise of immunotherapy to treat cancer was first realized over 100 years ago
(Figure
1). In 1890, Emil von Behring and Erich Wernicke found that animals infected with
diphtheria could be cured by injection of sera produced by animals immunized with
an attenuated form of diphtheria, and this treatment was successfully used to treat
a child with diphtheria in 1891.6 This introduced the use of serum as therapy and
for the first time showed that immunity could be transferred, thereby demonstrating
the clinical utility of passive immunity. The first application of immunotherapy in
oncology also occurred in 1891, when William B. Coley (known as the father of immunotherapy)
injected bacteria into a patient with cancer as a means of stimulating the immune
system to shrink the patient's tumor, a strategy that was successful.7
Since then, significant progress has been made in the understanding and application
of immunotherapy as monotherapy for cancer treatment. These agents can be classified
as either active therapies that induce an immune response in otherwise nonresponsive
patients or passive therapies that stimulate a patient's intrinsic immune response8
(Table
1). Active therapies include cytokines, immunomodulatory monoclonal antibodies (mAbs),
and cancer vaccines, and passive therapies include BiTE antibody constructs, bispecific
and multispecific antibodies, oncolytic viruses, cell‐based therapies, and tumor‐targeting
mAbs. The checkpoint inhibitors (e.g., PD‐1, PD‐L1, CTLA‐4, and LAG‐3) are immunomodulatory
mAbs that address immune escape by tumor cells that leverage normal immune‐suppressive
mechanisms to prevent autoimmunity and tissue damage in response to acute infection
in otherwise healthy individuals, but promote tumor progression in cancer patients.9
BiTE antibody constructs have dual specificity for T cells and cancer cells and bind
to an invariant component of a T‐cell receptor and a specific surface antigen on a
cancer cell (e.g., CD19), forcing them into proximity.10 Because they do not require
a T‐cell clone with a specific T‐cell receptor or an MHC class I or peptide antigen
for T‐cell recognition, BiTE antibody constructs can overcome immune escape. Oncolytic
viruses selectively kill cancer cells and stimulate the immune system (e.g., Imlygic),
while dendritic cell vaccines (e.g., sipuleucel‐T) involve the extraction of dendritic
cells from the patient, exposure of those cells to cancer cells or antigens, and reintroduction
of these now active immune cells to the patient (alternative approaches to vaccination
against cancer are also under investigation).11 Adoptive T‐cell therapies including
CAR‐T cell approaches depend on the genetic alteration of T cells to express particular
antigen receptors on their surface that can recognize and kill cancer cells.12 The
therapeutic use of neoantigens to stimulate T‐cell responses in cancer patients also
have potential, with data from mouse models showing that vaccination with neoantigens
can be effective.13 Immune system modulation by antibody‐dependent cellular cytotoxicity
and complement‐dependent cytotoxicity mechanisms has also been successfully achieved
with agents targeting CD20, CD52, SLAMF7, and CD38 showing clinical efficacy.
Table 1
Classes of immunotherapy agents in oncology
Active Immunotherapies
Classes
Examples
Cancer vaccines
Sipuleucel‐T
Cytokines
Interleukin‐2, interferon‐α
Immunomodulatory mAbs
Nivolumab, ipilimumab, pembrolizumab
Passive immunotherapies
Classes
Examples
Cell‐based therapies
Adoptive T‐cell therapy (e.g., TIL, TCR, CAR‐T)
Oncolytic viruses
T‐Vec
Bi‐ and multispecific antibodies
Blinatumomab
Tumor‐targeting mAbs
Rituximab
mAbs, monoclonal antibodies; TIL, tumor infiltrating lymphocytes; TCR, T‐cell receptor;
CAR‐T, chimeric antigen receptor T‐cell therapy; T‐Vec, Talimogene laherparepvec.
John Wiley & Sons, Ltd.
More than 15 cancer immunotherapies were approved for use as monotherapies in various
solid and liquid tumor indications and three combination immunotherapies were approved
as of 2015 (Table
2; refer to the United States product inserts [USPIs] for specific approved indications).
Currently, the majority of approved cancer immunotherapies and those in development
are biologics or cell‐based therapies, as these are ideal modalities to target protein–protein
interactions and signaling pathways. However, there is a significant opportunity for
the development of small molecule immuno‐oncology therapeutics,14 due to their unique
ability to modulate the activity of intracellular targets (e.g., indoleamine 2,3‐dioxygenase
[IDO1]), which are not easily accessible by a biologic. Through leveraging multiple
mechanisms of action and modalities of traditional cytotoxic agents, targeted agents
and biologic, and small molecule immunotherapies, various tumor types are treatable.
Table 2
FDA‐approved immunotherapy agents
Checkpoint inhibitors
MOA
Agent
Year
Indication
c
Anti‐PD1
Nivolumab
2014
Melanomaa, b
2015
Lung cancer, RCC
Anti‐PD1
Pembrolizumab
2014
Melanomaa, b
2015
Lung cancera, b
Anti‐CTLA‐4
Ipilimumab
2011
Melanoma
BiTE antibody constructs ; Bi‐ and multispecific antibodies
MOA
Agent
Year
Indication
c
CD3/CD19
Blinatumomab
2014
ALLa, b
Vaccines and oncolytic viruses
MOA
Agent
Year
Indication
c
Dendritic cell
Sipuleucel‐T
2010
Prostate cancer
Oncolytic virus
T‐Vec
2015
Melanoma
Cytokines
MOA
Agent
Year
Indication
c
Cytokine
IL‐2
1992
RCC
1998
Melanoma
Cytokine
IFN‐α
1986
HCL
1988
AIDS‐related Kaposi's Sarcoma Melanoma
1995
Melanoma
1997
NHL
mAbs
MOA
Agent
Year
Indication
c
CD52
Alemtuzumab
2001
CLL
CD20
Ofatumumab
2009
CLL
CD20
Rituximab
1997
NHL
2010
CLL
CD38
Daratumumab
2015
Multiple Myelomab
HER2
Trastuzumab
1998
Breast cancer
2010
Gastric cancer
EGF
Cetuximab
2004
Colorectal cancer
2011
Head/neck cancer
CD20 ADC
90Y‐Ibritumomab tiuxetan
2002
NHL
CD30 ADC
brentuximab vedotin
2011
Hodgkin lymphoma, ALCL
Cell‐based therapies
No TIL, TCR, or CAR‐T cell therapies are FDA approved
Combination Immunotherapies
MOA
Agent
Year
Indication
c
Cytokine + VEGF
IFN‐α+ bevacizumab
2009
Renal cancer
Anti‐PD1 + anti‐CTLA‐4
Nivolumab + ipilimumab
2015
Melanomaa, b
SLAMF7 + SOC
Elotuzumab + lenalidomide + dexamethasone
2015
Multiple Myelomab
a
Denotes approval via the FDA's accelerated approval pathway
b
Denotes priority review status. RCC, renal cell carcinoma; ALL, acute lymphoid leukemia;
MA, malignant ascites; HCL, hairy cell leukemia; NHL, Non‐Hodgkin's Lymphoma; IL‐2,
interleukin 2; IFN‐α, interferon alpha
c
Refer to the USPIs for specific information of each approved indication (e.g., histological
and molecular subtypes, line of treatment).
John Wiley & Sons, Ltd.
Combination immunotherapy landscape
Combination immunotherapies that involve various phases of the cancer–immunity cycle
may enhance the ability to prevent immune escape by targeting multiple mechanisms
by which tumor cells avoid elimination by the immune system, with synergistic effects
that may offer improved efficacy in broader patient populations (Figure
2). Current immunotherapy combinations involve combining multiple immunotherapies
or other cancer therapies such as chemotherapy, radiation, and targeted therapies
(Table
3). The US Food and Drug Administration (FDA) approvals of bevacizumab and interferon‐alpha
for the treatment of renal cancer in 2009 and nivolumab and ipilimumab for the treatment
of melanoma in 2015 reveal the potential for combination immunotherapies. The combination
of bevacizumab and interferon‐alpha resulted in a median progression‐free survival
(PFS) of 10.2 months vs. 5.4 months in the control group receiving interferon‐alpha
monotherapy.15 The combination of nivolumab and ipilimumab was also more effective
than the respective single agents. As monotherapies, these agents provided a meaningful
improvement in PFS and/or overall survival (OS) vs. standard of care. However, in
combination, these agents were even more effective, with an overall median PFS of
11.5 months for the combination of nivolumab and ipilimumab, compared with 2.9 months
and 6.9 months for ipilimumab and nivolumab alone.16 Although this increased efficacy
came at the cost of increased adverse events,16 which is not an unexpected result
for immunotherapy combination given the potential for overlapping toxicities, the
benefit/risk assessment resulted in the accelerated approval of this combination.
There was a strong mechanistic basis for testing the combination of nivolumab and
ipilimumab. While both are checkpoint inhibitors targeting negative regulators of
the immune system, they act on nonredundant regulatory pathways. Moreover, CTLA‐4
acts in the lymphoid system, while PD‐1 and PD‐L1 act downstream in the tumor microenvironment.17
The mechanisms of resistance to PD‐1 and CTLA‐4 inhibitors may therefore be addressed
by combination therapy (e.g., the CTLA‐4 blockade mitigates the CTLA‐4 upregulation
that may partially underlie resistance to PD‐1 blockade). These mechanisms are not
well understood and combination therapy does not completely resolve nonresponse, suggesting
additional mechanisms of resistance that need to be addressed with agents with other
mechanisms of action (MOAs). While many of the current combination trials are expansions
of the nivolumab and ipilimumab combination into other indications, novel combinations
of checkpoint inhibitors with vaccines, cytokines, and molecularly targeted agents
are also ongoing (Table
3).
Figure 1
History of immunotherapy. Key events leading to the development of currently marketed
immunotherapies including sipuleucel‐T (Provenge), ipilimumab (Yervoy), blinatumomab
(BLINCYTO), nivolumab (Opdivo), pembrolizumab (Keytruda), and talimogene laherparepvec/T‐Vec
(Imlygic).
Figure 2
Intervention in the cancer‐immunity cycle by immunotherapy agents. Overcoming resistance
and restoring a functional immune‐surveillance system requires leveraging multiple,
complementary mechanisms of action and agents that acts in multiple phases of the
cancer‐immunity cycle (numbers denote the phases at which each type of immunotherapy
acts).
Table 3
Selected list of combination immunotherapies in clinical development
Immunotherapy + Immunotherapy
Combination therapy
Mechanisms of action
Phase
Indication
Nivolumab + ipilimumab
Anti‐PD1 + anti‐CTLA‐4
I/II
Gastric, TNBC, PA, SCLC, Bladder, Ovarian
II/III
Melanoma, RCC
III
SCLC, GBM, NSCLC
Nivolumab + BMS‐986016
Anti‐PD1 + anti‐LAG3
I
Solid tumors
Nivolumab + viagenpumatucel‐L
Anti‐PD1 + vaccine
I
NSCLC
Nivolumab + urelumab
Anti‐PD1 + anti‐4‐1BB
I/II
Solid tumors, B‐cell NHL
Atezolizumab + MOXR0916
Anti‐PDL1 + anti‐OX40
I
Solid tumors
Atezolizumab + varlilumab
Anti‐PDL1 + anti‐CD27
II
RCC
Atezolizumab + GDC‐0919
Anti‐PDL1 + IDO inhibitor
I
Solid tumors
Epacadostat + atezolizumab, durvalumab, or pembrolizumab
IDO inhibitor + anti‐PDL1 or anti‐PD1
I/II
Solid tumors
Pembrolizumab + T‐Vec
Anti‐PD1 + vaccine
III
Melanoma
Durvalumab + tremelimumab
Anti‐PDL1 + anti‐CTLA‐4
I/II
Melanoma
I/II/III
SCCHN
II
Mesothelioma, UBC, TNBC, PA
III
NSCLC, Bladder
Pidilizumab + dendritic cell/RCC fusion cell vaccine
Anti‐PD1 + vaccine
II
RCC
Immunotherapy + Targeted Therapy
Combination therapy
Mechanisms of action
Phase
Indication
Atezolizumab + bevacizumab
Anti‐PDL1 + anti‐VEGF
II/III
RCC
Atezolizumab + cobimetinib
Anti‐PDL1 + MEK inhibitor
I
Solid tumors
Atezolizumab + vemurafenib
Anti‐PDL1 + BRAF inhibitor
I
Melanoma
Atezolizumab + erlotinib or alectinib
Anti‐PDL1 + EGFR or ALK inhibitor
I
NSCLC
Nivolumab + bevacizumab
Anti‐PD1 + anti‐VEGF
II
RCC
Pembrolizumab + pazopanib
Anti‐PD1 + tyrosine kinase inhibitor
I
RCC
Pembrolizumab + dabrafenib + trametinib
Anti‐PD1 + BRAF inhibitor + MEK inhibitor
I/II
Melanoma
Durvalumab + dabrafenib + trametinib
Anti‐PDL1 + BRAF inhibitor + MEK inhibitor
I/II
Melanoma
Nivolumab + sunitinib, pazopanib, or ipilimumab
Anti‐PD1 + RTK inhibitor, RTK inhibitor,
I
RCC
Immunotherapy + Chemotherapy
Combination therapy
Mechanisms of action
Phase
Indication
Nivolumab + platinum doublet chemoa
Anti‐PD1 + chemotherapy
III
NSCLC
Pembrolizumab + cisplatin
Anti‐PD1 + chemotherapy
III
Gastric
Pidilizumab + lenalidomide
Anti‐PD1 + chemotherapy
I/II
Multiple myleloma
Pidilizumab + sipuleucel‐T + cyclophosphamide
Anti‐PD1 + vaccine + chemotherapy
II
Prostate
Atezolizumab + carboplatin/paclitaxel +/– bevacizumab
Anti‐PDL1 + chemotherapy +/– anti‐VEGF
III
NSCLC
TNBC, triple negative breast cancer; PA, pancreatic adenocarcinoma; SCLC, small‐cell
lung cancer; RCC, renal cell carcinoma; GBM, glioblastoma multiforme; NSCLC, non‐smallcell
lung cancer; NHL, non‐Hodgkin's lymphoma; SCCHN, squamous cell carcinoma of the head
and neck; UBC, urothelial bladder cancer. aSquamous: gemcitabine + cisplatin or carboplatin;
Nonsquamous: pemetrexed + cisplatin or carboplatin.
John Wiley & Sons, Ltd.
Combination therapies may dramatically improve the outcome for cancer patients, and
indeed it is expected that such therapies will eventually become the standard of care
for cancer treatment, but the discovery of effective combinations is a challenging
endeavor. With nearly 200 molecules approved by the FDA for the treatment of cancer,
including over 15 immunotherapy agents, experimentally testing every possible combination
of these drugs would be unfeasible, even with high‐throughput experimental methods
and a mechanistic basis for the selection of agents with complementary MOAs that target
multiple mechanisms of resistance and immune escape. Therefore, new systems approaches
are needed to reduce the search space and prioritize combinations for experimental
testing. In addition, immunotherapies have unique properties that complicate their
clinical development, and are magnified in the context of combination therapies. The
regulatory environment is also evolving, particularly for novel agents including cell‐based
therapies, for which many of the traditional development paradigms are not applicable.
Preclinical development and clinical translation of safety/efficacy
The objectives for preclinical evaluation of cancer immunotherapies are identical
to other anticancer drugs and substantial progress has been made in the field of translational
cancer research. These objectives include the (i) identification of the pharmacological
characteristics of a development molecule, (ii) determination of an initial safe and
starting dose for human studies, and (iii) understanding of the toxicological profile
of the development molecule. However, for cancer immunotherapies there are unique
challenges in translating preclinical data to the clinic, including cell lines or
animal models that do not adequately mimic the tumor, tumor microenvironment, human
immune response, or the propensity to develop resistance.
The starting dose in first‐in‐human (FIH) trials of anticancer agents should be carefully
selected using all available nonclinical data (e.g., pharmacokinetics, pharmacodynamics
[PK/PD], and toxicology) prior to the initiation of clinical studies. Specifically,
both the estimated highest recommended starting dose from the most sensitive species
from toxicology results and the minimal anticipated biological effect level (MABEL)
from preclinical PK/PD results are important data sets to inform FIH dose selection.18
For cancer immunotherapies, MABEL appears to be the most common approach for FIH dose
selection. For example, the no‐observed‐adverse‐effect‐level (NOAEL) of nivolumab
(as determined in repeat‐dose toxicology studies in cynomolgus monkeys) was 50 mg/kg;19
however, the FIH dose was 0.1 mg/kg, presumably on the basis of preclinical pharmacology
data that suggested a much lower MABEL than NOAEL. For ipilimumab, the NOAEL was 10 mg/kg20
and the FIH dose was 0.3 mg/kg. Similarly, the NOAEL for pembrolizumab was 200 mg/kg/day,21
yet the starting dose in patients with NSCLC was 1 mg/kg.
To define the MABEL from preclinical studies for FIH trials, knowledge of the PK/PD
relationship is essential. Human PK prediction is an essential component in predicting
the human dose corresponding to MABEL. For small molecules, the prediction of human
PK is typically achieved using an empirical allometric scaling approach of data obtained
from multiple preclinical species. For biologics that demonstrate linear PK, single‐species
allometric scaling can generally provide reasonable estimates of human PK.22 In theory,
this single‐species approach could also apply to mAbs with nonlinear clearance that
have high therapeutic doses where the target‐mediated clearance is saturated and the
overall clearance is in the linear range. However, in this situation the animal data
used for the human PK projection would need to be in the linear range as well.
In terms of the prediction of human PD (either biomarkers or exploratory end points
in early development) and human efficacious dose projection, PKPD modeling holds a
unique position in translational research to integrate diverse sets of preclinical
information. However, animal models for cancer immunotherapy present very unique challenges.
Not only is there a time delay in tumor response, but the interaction between the
tumor and mouse immune system is uniquely complex due to the involvement of multiple
cell types across different tissue compartments.23 For combination therapy, a synergistic
effect of the combination further increases the complexity of the correlation between
drug exposure and antitumor response. In this situation, mechanistic‐based physiologically
based pharmacokinetic (PBPK) and quantitative systems pharmacology (QSP) models may
have a significant advantage in helping to capture the complex dynamics observed in
preclinical models to predict human PD.
In both monotherapy and combination settings, it is challenging to identify suitable
preclinical models that predict human efficacy and safety. It may be necessary to
utilize all relevant information, including novelty of the agent, mechanism of action,
nature of the target, relevance of animal species and models, potential pharmacological
impact of genetic polymorphisms, dose–response, and exposure–response.24 Since a combination
of a cancer immunotherapy with other immunotherapies or anticancer agents may cause
unexpected toxicities, the starting dose of the agents in combination should generally
be lower than the maximum tolerated dose (MTD) or the highest tested safe dose in
monotherapy to avoid severe adverse events by overlapping or unexpected toxicities.
Preclinical studies may also be useful in the evaluation of potential additive or
synergistic toxicities of the combination.
For effector cell therapy, the traditional approaches used to select the FIH starting
dose may not be applicable. Since it is a highly individualized therapy, multiple
variables, including disease, treatment conditions, and potential for immune reactions
need to be considered during dose selection for adoptive cell‐based immunotherapies.
Currently there are no clear standards in place to guide the selection of a starting
dose for adoptive cell‐based therapies. Published clinical trial results to date indicate
that most treatment doses for CAR‐T cell therapies were falling within a similar range
of roughly 106–107 cells/kg.25, 26 To date, there is not an apparent correlation between
T‐cell dose and clinical response or between T‐cell dose and various toxicities.27
However, it appears that lower T‐cell dosing may achieve effective clinical outcomes
with a reduced potential for uncontrolled cellular proliferation associated with cell‐based
therapies.27
In order to begin clinical studies, global health authorities require the submission
of adequate information from preclinical pharmacological and toxicological studies
that form the sponsor's position that it is reasonably safe to conduct human studies.
To support sponsors in the generation of the preclinical data package needed for clinical
evaluation, there are various guidances available from the International Conference
on Harmonization (ICH), the FDA, European Medicines Authority (EMA), and Japan Pharmaceuticals
and Medical Devices Agency (PMDA),18
,
28, 29, 30, 31, 32 including specific guidelines for cancer immunotherapies.33, 34,
35 For combinations of new investigational drugs (including, but not limited to, cancer
immunotherapies), the FDA has recently published a guidance to assist sponsors in
the codevelopment of two or more new investigational drugs;36 referred to here as
2+ new molecular entity (NME) combinations. Briefly, the FDA believes that codevelopment
is appropriate when there is a strong biological rationale for the combination and
the nonclinical characterization of activity of each agent alone and in combination
suggests that the combination would provide activity superior to each individual agent
and available therapies. In general, with the rapid advances in technology and increasing
number of combinations within and between cancer immunotherapeutic products, it is
anticipated that additional guidance documents will be available in the future. However,
as each clinical trial application is evaluated on a case‐by‐case basis, close and
frequent interactions with health authorities are encouraged and advised, particularly
for gene‐ and cell‐based products.
CLINICAL DEVELOPMENT AND TRIAL DESIGN
Strategies to identify efficacious dose(s)/schedule(s) for late‐stage clinical development
In the current oncology drug development paradigm, trials are designed to maximize
the chance of an effective therapy and often include patients with advanced disease
and a limited life expectancy. Based on the strategies that were originally developed
for cytotoxic chemotherapies, dose selection for the clinical development of targeted
agents and cancer immunotherapies are typically based on the MTD, which is commonly
identified in phase I studies and oftentimes with a limited knowledge of long‐term
tolerability. For traditional oncology molecules (e.g., chemotherapy, targeted agents),
it is also common for the recommended phase II dose (RP2D) to also be the MTD. The
selection of the MTD as the RP2D for cancer therapeutics is commonly based on the
assumption that greater efficacy is associated with a higher dose; however, this approach
has multiple limitations.37 For example, identification of the MTD from early clinical
studies (e.g., phase I) is commonly confounded by the study designs typically employed.
Phase I studies are commonly small, with large interindividual variability (due to
the large diversity of tumor types and disease burden), and individualized treatment
regimens. Phase II studies, while larger than phase I studies, with only select tumor
types, do not typically explore dose levels lower than the MTD or RP2D identified
from the phase I study/studies that could help to better define dose–response (PK/PD)
relationships. Despite its limitations, this approach has long been successfully employed
for single‐agent development, but it may not be suitable for immunotherapies developed
in combination.
For cancer immunotherapies, the MTD‐based approach to identify the RP2D is particularly
challenging. The assumption of a monotonic increase in efficacy with increasing dose
may not be appropriate for immunotherapies that require a balance of a boosting of
the immune system to combat cancer while avoiding overstimulation.38 In addition,
the identification of an MTD for immunotherapies may not be achievable. For example,
in single‐agent phase I studies with nivolumab39, 40 (up to 10 mg/kg), pembrolizumab
(up to 10 mg/kg),41 and ipilimumab42 (up to 20 mg/kg) an MTD was not identified. An
ipilimumab dose of 10 mg/kg was used in subsequent clinical trials based on preclinical
data that suggested the concentrations achieved at this dose provided a maximal effect;
ultimately, a dose of 3 mg/kg was approved. The inability to identify an MTD is also
commonly the case with cancer vaccines due to their flat dose–toxicity curve.33 A
single MTD was identified for the combination of nivolumab and ipilimumab, but only
four combinations of doses were tested, and it is likely that multiple MTDs exist
for combination therapies. For example, in a phase I study of neratinib and temsirolimus
(nonimmunotherapy cancer agents), 12 dose combinations were explored and the combinations
of 200 mg neratinib with 25 mg temsirolimus and 160 mg neratinib with 50 mg temsirolimus
were identified as MTDs.
Clearly, the difficulty in either establishing an MTD for an immunotherapy administered
as a single agent or establishing a single MTD for combination therapies complicates
the selection of the RP2D dose, and prevents the historically straightforward approach
of selecting the MTD as the RP2D. In cases such as this, the RP2D should be based
on a benefit/risk assessment and comprehensive exploration of the surface contour
describing the relationship between exposure, safety and tolerability, and response;
such an assessment has always been the basis for selecting the RP2D dose, it has simply
been a relatively straightforward assessment when an MTD is easily identified. Indeed,
because the benefit/risk comparison at different doses levels during clinical development
of ipilimumab was inadequately characterized, the FDA issued a postmarketing requirement
to compare the efficacy at the approved dose (3 mg/kg, Q3W) to efficacy at a higher
dose (10 mg/kg, Q3W) for patients with unresectable stage III or stage IV melanoma.
The sheer number of “tunable” variables in a combination regimen, including dose level,
administration frequency, the length of the dosing holiday, the duration of treatment
for each dose, and the sequence of administration for each drug, and the inability
to explore all possible combinations of these variables in clinical trials, complicates
the situation further for combination immunotherapies. To overcome these challenges,
novel trial designs that explore the dose–response surface for combination immunotherapies
can be implemented and complemented by model‐based analyses to better understand the
therapeutic window of these combinations.
The use of patient‐reported outcomes (PRO) to inform dose selection are also recommended
in early clinical development, given the tolerability and adherence issues associated
with these drugs, although PROs are rarely included in the labeling of oncology drugs
in the US (although they are more common in Europe and for nononcology drugs in the
US).43 While patient tolerance for side effects of anticancer drugs may be higher
due to the severity of the disease, many patients discontinue cancer therapy as a
result of adverse events, and this issue may be more prevalent for immunotherapies
as the duration of treatment and response to these molecules is prolonged. For example,
in clinical trials 9% of patients on nivolumab discontinue treatment due to adverse
events, 26% experience a dose delay, mainly due to adverse events, and 42% experience
a serious adverse reaction,44 while discontinuation rates (due to adverse events)
up to 50% have been reported for the highest approved dose of ipilimumab of 10 mg/kg.45
Approximately 50% of patients receiving a combination of nivolumab and ipilimumab
discontinued treatment due to adverse events.46 Adherence to the dosing regimen may
also negatively impact efficacy and is commonly a result of adverse events, with adherence
rates as low as 52% reported for anticancer therapeutics.47
Application of modeling and simulation to inform clinical development
To identify the optimal dose and schedule of a cancer immunotherapy, it is advantageous
to apply a more strategic approach that integrates multiple data sources throughout
various stages of development (Figure
4). Specifically, a quantitative, model‐based approach that integrates exposure–response
(i.e., biomarker and/or efficacy) analyses with exposure–safety analyses may provide
useful information on the benefit/risk profile of a drug candidate and inform dose
selection. In early development, exposure–response analyses typically involve the
assessment of tumor growth inhibition, with specific guidelines for assessment outlined
in the Response Evaluation Criteria in Solid Tumors (RECIST) and the Immune‐Related
Response Criteria (irRC).48 The predictive value of tumor assessments with respect
to overall survival has been established for traditional cytotoxic drugs, and data
from the development of nivolumab and ipilimumab suggest that there is also a relationship
between tumor size assessments in early development and overall survival for immunotherapies.23
It may also be of value to assess other biomarkers of response that leverage the effects
of immunotherapies on the immune system, such as cytokine elevation and markers of
T‐cell activation.
The application of exposure–response analyses may have a significant impact on development
and approval. In a phase I study of nivolumab in multiple solid tumor indications,
for example, the same dose escalation scheme was used for each indication, but different
doses were chosen for the expansion phases.40 However, exposure–response modeling,
in which the relationship between dose/exposure and receptor occupancy, adverse events
leading to discontinuation, objective response rate, progression‐free survival, and
tumor growth dynamics was assessed, supported the selection of a common dose of nivolumab
for melanoma, non‐smallcell lung cancer (NSCLC), and renal cell carcinoma, with no
postmarketing commitment to evaluate additional dose levels.49 Exposure–response modeling
also supported the selection of the dose for pembrolizumab; doses of 2 mg/kg Q3W or
10 mg/kg Q3W were studied and the 2 mg/kg Q3W was approved on the basis of the exposure–response
analyses, which showed that the higher dose level was not associated with additional
treatment benefit.
Systems pharmacology approaches can also elucidate the underlying mechanisms of cancer
immunotherapies,50 and provide useful information on the schedule and sequencing of
administration of various agents within a combination. Novel clinical trial designs
complement these approaches, as they allow for the collection of the necessary data
to inform them, which is otherwise too sparse to allow these approaches to be applied
effectively. The success of these approaches, particularly early in development, also
depends on the identification of biomarkers of efficacy and safety signals (see Biomarkers
section below).
The lessons from ipilimumab are also informative and speak to the value of quantitative
modeling. A pooled exposure–response analysis including almost 500 patients from four
studies showed exposure‐dependent efficacy and safety at doses of 3 mg/kg (approved
dose for unresectable or metastatic melanoma) and 10 mg/kg51 The approved dose of
ipilimumab in unresectable or metastatic melanoma (3 mg/kg) is currently being compared
with the 10 mg/kg dose in a phase III postmarketing requirement (PMR) clinical trial
to better characterize the risk/benefit profile, given the model predictions of increased
efficacy and adverse events with higher doses.51, 52 The activity of pembrolizumab
was unaffected by dose or schedule in randomized trials,53 and exposure–response analysis
also provided support for the approved dose of 2 mg/kg Q3W.49, 54
Quantitative systems pharmacology (QSP) modeling offers another promising approach
to elucidate the complex biology of combination immunotherapies.55, 56 Translating
the clinical experience with single‐agent immunotherapies into phase I, phase II,
and phase III combination doses is not straightforward, particularly if the clinical
trials are not designed to support exposure–response analyses. Quantitative systems
pharmacology takes a network‐centric, holistic view of biology, and by quantitatively
describing the pathophysiology of disease has the potential to help address these
needs.
Since QSP models capture a drug's mechanism of action, they can help identify and
prioritize targets, explore biomarkers of response, and identify potential characteristics
by which to stratify patients. Mechanistic QSP models can be interrogated to assess
mechanisms of tumor immunosuppression and means to circumvent them and the effect
of disease severity and progression on treatment outcomes. Such models are particularly
useful in combination immunotherapy development. Unlike traditional exposure–response
analyses, which are top‐down approaches dependent on the availability of sufficient
clinical data, these bottom‐up and middle‐out approaches could be used for prior predictions
of synergistic interactions and their effect on efficacy and safety.
PBPK modeling is another quantitative, mechanistic approach that has proven useful
in the development of immunotherapies, as demonstrated by its application to blinatumomab
development. Drug–drug interactions (DDIs) are not common for biologics, but immunotherapies
are a special case due to their potential impact on cytokine‐mediated changes in cytochrome
P450 activity (see “Clinical Pharmacology Considerations,” below).57 Indeed, transient
elevations in cytokine levels are observed after blinatumomab administration. In this
case, the potential for cytokine‐mediated DDI was predicted based on data from in
vitro hepatocytes incubated with blinatumomab or cytokines and the clinical cytokine
profiles.58 The model predicted little potential for DDI and, as a result of this
prediction, no clinical DDI studies were conducted.
Model‐based meta‐analyses are another tool to compare treatments without head‐to‐head
clinical trials, link biomarker response to clinical efficacy, and bridge across populations
and indications.59 This approach leverages both internal and external data and complements
the exposure–response modeling, quantitative systems pharmacology, and PBPK modeling
approaches. All have the potential to inform and even accelerate the development of
immunotherapies, but successful implementation is not without its obstacles. Without
prospective planning to include modeling in the clinical development plan, the data
available to inform these models may be insufficient. Such challenges are magnified
in the context of combination immunotherapy development, where uncertainties are magnified
and therefore require even more data to develop reliable models.
Novel clinical trial design to support model‐based dose selection for combination
regimens
A modified 3+3 approach to trial design is frequently employed for combination studies,
in which one agent is administered at its approved dose and schedule and the dose
of the other agent(s) is/are gradually increased until a combination MTD is found.
The phase I study of nivolumab (Dose B) and ipilimumab (Dose A) used the traditional
3+3 design (as outlined in Figure
3, with the addition of a cohort treated at a lower dose of ipilimumab),60 and the
combination of nivolumab with lirilumab also used this scheme, studying increasing
doses of lirilumab combined with 3 mg/kg nivolumab.61 However, this approach offers
only a narrow exploration of the dose–toxicity contour (Figure
3), even when variations on this study design are employed. It is also challenging
to know which agent should be considered the main driver of the response and thus
would be appropriate to be dosed at its MTD, if established, or the approved dose
and schedule, an even more challenging task for bispecific antibodies in which the
dose titration of the individual pharmacophores cannot be carried out independently.
Figure 3
Dose–response contour for rule‐based and model‐based clinical trial designs. Doses
explored relative to the dose–toxicity contour using a traditional, rule‐based method
vs. a model‐based design. DLT, dose‐limiting toxicity. Trials based on rule‐based
designs typically maintain the dose of one agent as a constant while escalating the
dose of the other agent, resulting in a narrow exploration of the dose–toxicity contour.
Trials utilizing model‐based designs may vary the doses of both agents to more comprehensively
explore the dose–toxicity contour.
Figure 4
The role of modeling and simulation in combination immunotherapy development. (a)
Modeling and simulation approaches used to answer questions during preclinical and
clinical development and life‐cycle management. (b) Iterative cycle between experimentation,
modeling, prediction, analysis, and the generation of new, testable hypotheses. LCM,
life‐cycle management; FIH, first‐in‐human; PD, pharmacodynamics; PKPD, pharmacokinetics/pharmacodynamics;
PBPK model, physiologically based pharmacokinetic model; DDI, drug–drug interaction.
Rather, alternative rule‐based strategies, such has the 3+3+3 design, the accelerated
titration design, and nonparametric up‐and‐down designs, and model‐based approaches
(reviewed by Le Tourneau et al.62) may provide value by expanding the characterization
of the dose–toxicity contour (Figure
3).63 Moreover, through the identification of multiple MTDs of the combination and
integrating that data with the exposure–response data, an RP2D with a greater likelihood
of achieving maximum efficacy with acceptable safety may be determined. Simulation
studies suggest that model‐based trial designs may also treat more patients at optimal
or near‐optimal doses and expose fewer patients to subtherapeutic doses. Although
criticized for potentially long trial durations, simulation studies suggest that trials
employing the CRM method may be of comparable length to trials employing traditional
designs.
However, model‐based designs are almost never used.62 This is likely due to the difficulty
of implementing such designs, with their dependence on reliable biomarkers, real‐time
modeling and sample assessments, the lack of familiarity with the designs, and the
potential for regulatory hurdles when employing such designs. The rule‐based, nonparametric
up‐and‐down trial design employed to study the combination of neratinib and temsirolimus
represents a reasonable compromise between fully adaptive, model‐based designs and
the traditional designs like the 3+3 (for specific details on the trial design, refer
to references 64 and 65).64, 65 It was straightforward to operationalize, but still
offered superior performance and exploration of many more dose levels than would typically
be studied.64
Patient selection
One of the promises of immunotherapies lies in reinitiating a self‐sustaining cycle
of cancer immunity that results in potentially deep and durable clinical response.4
Favorable efficacy was observed in patients treated with checkpoint inhibitors, including
ipilimumab, where ∼20% of melanoma patients appear to receive long‐term clinical benefits
(with >10 years survival).66 For combinations of cancer immunotherapies, an important
question is whether it is possible to further expand the “responder” population by
combining checkpoint inhibitors with agents with a complementary mechanism of action
in the cancer‐immunity cycle.4 As there is large variability in tumor biology across
patients and tumor types, the strategy to develop combination therapy and patient
selection needs to take into account the underlying variability in tumor biology.
A rational patient selection strategy for cancer drug development will rely on a thorough
understanding and characterization of tumor biology and cancer‐immunity interactions.
While clinical trials for traditional cytotoxic agents typically include a heterogeneous
patient population, patient stratification on the basis of such factors as tumor type,
target expression on tumor cells and T cells, and tumor mutational load may increase
the probability of success for combination immunotherapies.
It is hypothesized that the major barriers to therapeutic efficacy differ for “inflamed”
and “noninflamed” tumors, and thus the patient stratification strategy should also
consider the condition of the tumor microenvironment. In general, tumors can be considered
as “inflamed” or “noninflamed” based on the level of preexisting immune response in
the tumor microenvironment.17 For inflamed tumors, the cancer‐immunity cycle is likely
intact up until the point of tumor cell killing by T cells, which can be subdued by
PD‐L1:PD‐1 interaction. aPD‐1/aPD‐L1 treatments (e.g., nivolumab, pembrolizumab, atezolizumab)
can restore the effector function of preexisting anticancer T cells rapidly, and thus,
preexisting immune response has been shown to be desirable for efficacy. Similarly,
the expression of PD‐L1 on immune and tumor cells has shown to be correlated with
efficacy and thus was used as a patient selection strategy for aPD‐1/PD‐L1 treatments
in multiple tumor types.67, 68, 69 Recently, pembrolizumab was approved for use with
a companion diagnostic, the PD‐L1 IHC 22C3 pharmDx test, the first test designed to
detect PD‐L1 expression in non‐smallcell lung tumors.70 In contrast, antitumor responses
were observed in patients treated with the combination therapy of ipilimumab and nivolumab
regardless of tumor cell expression of PD‐L1 at baseline.46, 60 Similarly, the combination
of tremelimumab (aCTLA‐4) and durvalumab (aPD‐L1) shows clinical activity regardless
of PD‐L1 status at baseline.71 These data suggest that it may not be appropriate to
use baseline PD‐L1 expression as a selection criteria for all cancer immunotherapies,
particularly in combinations with multiple modes of actions. While the mechanism for
the combination effect remains an active area of research, it is hypothesized that
aCTLA‐4 treatment may drive T cells into the tumor microenvironment, leading to a
more favorable microenvironment for aPD‐1 efficacy.72 It is also possible that PD‐L1
expression on tumor‐infiltrating immune cells may be of relevance in addition to expression
on tumor cells.69
In contrast, noninflamed tumors represent microenvironments that lack a preexisting
immune response. In these cases, additional interventions are likely required to enable
immune recognition and T‐cell infiltration.17 While the underlying mechanisms responsible
for the lack of T‐cell infiltration are not well understood, combination strategies
aim to increase the frequency of antitumor T cells by various approaches including
tumor vaccine, adoptive T‐cell transfer, and augmenting the activity of costimulating
pathways.17 The FDA and EMA recently approved the first‐of‐its‐kind oncolytic virus,
Imlygic, for the local treatment of unresectable melanoma lesions, which highlights
the clinical significance of inducing immune inflammation within the tumor microenvironment.73,
74 The importance of tumor mutational heterogeneity in cancer is an active topic of
research and may play a significant role in patient selection for combination therapies.75
Tumor mutational load has been shown to correlate with clinical response to checkpoint
blockade in human cancers.76 Research by Snyder et al. suggests that somatic neoepitopes
were associated with a prolonged benefit in responders to aCTLA4 treatment in melanoma.77
From a practical perspective of the clinical development of combination therapies,
it is useful to think about whether the combination therapy is expected to provide
the most benefit in responders vs. nonresponders to prior immunotherapy, or in diagnostic‐positive
vs. diagnostic‐negative populations. For combinations with immune checkpoint inhibitors,
prior‐responders to checkpoint inhibitors or patients with high PD‐L1 expression may
represent a population with a generally intact cancer‐immunity cycle, and thus, in
this patient population, there may be a reasonable probability of success in identifying
an effective combination therapy that aims to address the potential resistance mechanisms.
In contrast, as there is less known about the underlying mechanisms that account for
nonresponders to immune checkpoint inhibitors, it may be rather difficult to identify
effective combination therapies that can potentially overcome multiple suppression
barriers in the cancer‐immunity cycle. However, as multiple cancer immunotherapies
are now approved therapies, it becomes more difficult to demonstrate superior efficacy
in randomized studies where the comparator has favorable efficacy. As such, there
may be an interest to target a nonresponder to prior immunotherapy or PD‐L1‐low expresser
population as a potentially attractive development option, especially if accelerated
approval (FDA), conditional marketing authorization (EMA), or SAKIGAKE “pioneer/forerunner”
(PMDA) is a potential development strategy of interest.
Biomarkers
Biomarker data can be useful in guiding dose and regimen selection in early clinical
development. For nivolumab, peripheral blood receptor occupancy and its associated
time course of PD‐1 on circulating CD3+ T cells were evaluated as potential PD markers
and compared across multiple dosing regimens in refractory solid tumors.39 It was
inferred from the data that shorter dosing intervals might increase occupancy and
tissue penetration and should be explored in later development. For blinatumomab,
peripheral cytokine levels were used as a PD marker for acute safety assessment and
contributed to the stepwise dosing recommendation for blinatumomab, in which the dose
is increased after the first week of treatment to reduce the potential for acute cytokine
release in patients with non‐Hodgkin's lymphoma.78 In addition, the exposure–response
relationship for peripheral B‐cell depletion was modeled and compared with that for
tumor size change. The difference in the two exposure–response curves provided potential
insight into translating peripheral B‐cell response to tumor response, including the
accessibility of tumor to the drug. As mentioned earlier, for pembrolizumab higher
baseline tumor expression of PD‐L1 has been associated with better efficacy in multiple
tumor types and, as a result, a companion diagnostic tool was recently approved for
pembrolizumab in 2L NSCLC.67, 68, 69, 70 Therefore, it is useful to consider including
baseline PD‐L1 expression status as a covariate in the exposure–response analyses,
as appropriate.
Similar principles of biomarker‐informed dose selection could be applicable to combination
drug development, with an added component that accounts for the interplay between
the combined therapeutic agents. For example, combined blockade of PD‐1:PD‐L1 with
other coinhibitors, such as TIM‐3, CTLA‐4, and LAG‐3, has a synergistic effect in
reversing T‐cell exhaustion and restoring CD8+ effector function.79 Engagement of
costimulatory receptors such as OX40, CD137, or CD27 can affect T‐cell activation,
proliferation, migration, and development of memory T cells.80 Thus, the “combined
effects” and associated biomarkers of therapeutic agents will require a deep understanding
of the underlying biology of the mechanism of action of each therapy and their respective
role in the cancer‐immunity cycle.
CLINICAL PHARMACOLOGY CONSIDERATIONS
The majority of approved immunotherapies are biologics (e.g., mAbs, vaccines, viruses)
or cellular‐based therapies (Table
3). For biologic cancer immunotherapies, the clinical pharmacology considerations
are consistent with other types of biologic therapeutics (for review, see Zhao et al.).81
Similarly, for small molecule immunotherapies, the clinical pharmacology characteristics
and assessments follow the traditional small molecule development paradigms for other
therapeutic areas.82 For vaccines and cell‐based therapies, there is currently limited
knowledge of their clinical pharmacology properties. Depending on the construct and
the drug delivery vehicle, the absorption, distribution, metabolism, and elimination
(ADME) properties can differ widely between different cancer vaccines.83
Dedicated studies to evaluate the impact of renal or hepatic impairment on the pharmacokinetics
of a biologic are not typically required, nor are they typically conducted for biologic
immunotherapies. However, population PK analyses are sometimes used to support the
lack of an impact of hepatic/renal impairment on the PK of a cancer immunotherapy
biologic. For example, population PK analyses for ipilimumab evaluated the impact
of mild/moderate renal impairment, baseline aspartate transaminase (AST), total bilirubin,
and alanine transaminase (ALT) levels on the ipilimumab PK and none of these variables
were demonstrated to have a clinically significant impact on ipilimumab exposure.52
As with all biologics, cancer immunotherapy biologics also have the potential for
immunogenicity, which may have an impact on their efficacy and safety. Briefly, the
formation of antidrug antibodies (ADAs) can impact efficacy by altering the pharmacokinetics
of the biologic by impacting clearance mechanisms and by targeting domains critical
for efficacy. In addition, potential safety consequences are variable and unpredictable,
and may include anaphylaxis, cytokine release syndrome, and/or crossreactivity to
endogenous proteins.84 Assessments of ADAs should follow the normal paradigms for
biologics.84 ADAs were assessed in clinical studies with blinatumomab and nivolumab
in which no association was observed between the development of ADAs and adverse events.85,
86 Immunogenicity of the combination of nivolumab and ipilimumab was also assessed
and included as a covariate in the population PK model, which suggested that ADAs
of these therapies do not have a clinically meaningful impact on exposure.87, 88 It
should be noted that these results are not generalizable and ADAs should be evaluated
in the clinical development programs for each cancer immunotherapy biologic.
Drug–drug interaction (DDI) studies, which are not typically conducted for biologics,
may be required for biologic immunotherapies due to the potential for cytokine‐mediated
alterations in drug metabolism. It has been observed that cancer immunotherapies influence
cytokine levels, and it has also been established that the activities of select cytochrome
P450 enzymes (the major metabolic pathway for small molecules) are altered in the
presence of cytokines.57 Therefore, there is a potential for a clinically relevant
DDI to occur, and thus both the FDA and EMA recommend assessing the potential for
a cytokine‐mediated DDI. Unfortunately, currently available in vitro and in vivo models
are not reliable predictors of a cancer immunotherapy‐mediated DDI. Therefore, clinical
evaluation of the DDI potential is the recommended approach by health authorities.
Due to the long terminal half‐life of biologics, crossover study designs are challenging.
In addition, due to toxicity concerns and the potential for immunogenicity, studies
often need to be conducted in cancer patients. As an alternative to dedicated clinical
DDI studies, several sponsors have used population PK approaches or PBPK modeling
approaches to characterize the potential for their drug to be a victim of DDI and
to support their product approval without conducting a dedicated drug–drug‐interaction
study.88, 89 Through the collection of proinflammatory cytokine data in early clinical
development of immuno‐oncology agents, the risk of a cytokine‐mediated DDI can be
evaluated without the need for dedicated DDI studies.
SAFETY AND TOLERABILITY CONSIDERATIONS FOR CANCER IMMUNOTHERAPY COMBINATIONS
Although cancer immunotherapies offer significant antitumor benefits, they are associated
with a unique side effect profile. Adverse events associated with immune checkpoint
inhibitors (e.g., ipilimumab, nivolumab) are autoimmune in nature and are commonly
referred to as “immune‐related adverse events” (irAE). In general, these irAEs of
checkpoint inhibitors include rash, diarrhea, colitis, autoimmune hepatitis, arthritis,
pneumonitis, and endocrinopathy.90 In contrast, the most common treatment‐emergent
adverse events of CD19 CAR T‐cell therapy and the bispecific T‐cell‐engaging (BiTE)
antibody, blinatumomab, are cytokine release syndrome and neurological toxicity.26,
86 However, with careful monitoring and early intervention, both the irAEs of checkpoint
inhibitors and cytokine release syndrome and neurological toxicity of CD19 CAR T‐cell
therapy and blinatumomab are treatable and reversible with established management
guidelines.91, 92, 93
As combinations of cancer immunotherapeutics have the potential for enhanced efficacy,
they also have the potential for increased toxicity. This was recently observed in
randomized, double‐blind phase III study of combined nivolumab and ipilimumab or monotherapy
in previously untreated metastatic melanoma.16 Briefly, grade 3/4 treatment‐related
adverse events (trAEs) were observed in 16% and 27% of patients treated with nivolumab
or ipilimumab monotherapy, respectively. However, when treated in combination, grade
3/4 trAEs were observed in 55% of patients. These trAEs lead to treatment discontinuation
in 9%, 15% and 38% of patients treated with nivolumab alone, ipilimumab alone, and
nivolumab/ipilimumab combination, respectively. While the rate and severity of the
trAEs increased with combination treatment relative to each monotherapy, there were
no new safety signals and the AEs appeared to be immune‐related and manageable with
established treatment guidelines.
The potential for increased toxicity was also observed with combinations between a
cancer immunotherapy and a targeted therapy, as was the case with the combination
of ipilimumab and the BRAF inhibitor, vemurafenib, two agents approved for the treatment
of advanced melanoma. This combination was supported by nonclinical data suggesting
that BRAF inhibitors may enhance immune‐cell function and antigen presentation and
clinical data suggesting minimal overlapping single‐agent toxicities of these two
therapies.94 However, in a phase I study evaluating the concurrent administration
of vemurafenib and ipilimumab, dose‐limiting hepatotoxicity was observed, halting
further enrollment.94 The results of this study highlight the importance of optimization
of combination regimens of cancer immunotherapy and molecularly targeted agents, despite
their distinct mechanism of action and individual safety profiles.
While it is more common for AEs to increase with cancer immunotherapy combinations,
there are some examples where the distribution of toxicities changes when a checkpoint
inhibitor is combined with chemotherapy. With ipilimumab monotherapy, the rate of
treatment‐related diarrhea and colitis (≥grade 3) was ∼8–23%.95 However, when ipilimumab
was dosed in combination with dacarbazine or fortumustine, the rate of ≥grade 3 diarrhea/colitis
was reduced to 4% and 5%, respectively.96, 97 In contrast, the rate of autoimmune
hepatitis increased with each combination, with ∼20% and 14% of patients experiencing
a grade 3 or 4 increase in ALT and/or AST with ipilimumab plus dacarbazine or fortumustine
treatment, respectively, compared with the typical rate of ipilimumab monotherapy
of 3–7%.95, 96, 97
Currently, the majority of experience with cancer immunotherapy combinations has been
limited to combinations with ipilimumab. However, recent data suggest that combinations
with PD‐1/PDL‐1 immune checkpoint inhibitors may be more tolerable. Epacadostat (INCB024360),
a small molecule inhibitor of the immune modulator indoleamine 2,3‐dioxygenase I,
is being investigated in multiple phase I studies in combination with ipilimumab,
pembrolizumab, durvalumab, or atezolizumab (NCT01604889, NCT02178722, NCT02318277,
NCT02298153, respectively). As a single agent, epacadostat was generally well tolerated
at doses up to 700 mg b.i.d., with no single‐agent MTD identified.98 An ongoing phase
I/II study evaluating epacadostat in combination with ipilimumab showed a favorable
response rate; however, ≥grade 3 irAEs occurred in 23% of patients evaluated at doses
from 25 mg b.i.d. up to the combination MTD of 50 mg b.i.d. epacadostat.99 In combination
with pembrolizumab, there is also an encouraging response rate; however, the toxicity
profile is more favorable than the ipilimumab combination, with grade 3 trAEs observed
in 11% of patients at doses from 25 mg to 300 mg b.i.d. epacadostat.100
The toxicity profile of immuno‐oncology combinations is just beginning to be understood.
From the limited experience thus far, trAEs appear to increase in rate and severity
with cancer immunotherapy combinations; however, depending on the combination partner,
alterations in the toxicity profile are also possible. Therefore, when combining an
immunotherapy with another treatment modality, it is important to determine the optimal
dose, schedule, and sequence. In addition, the patient selection strategy should take
into account the individual patient's performance status and the overall benefit/risk
ratio of the various therapies for the patient, particularly in patients with preexisting
autoimmune diseases.
REGULATORY CONSIDERATIONS AND MEANS TO ACCELERATE APPROVAL
Regulatory agencies worldwide have shown significant interest in cancer immunotherapies
through the recent approvals of multiple cancer immunotherapies including mAbs administered
as monotherapies (e.g., nivolumab, pembrolizumab, ipilimumab) or in combination (e.g.,
nivolumab/ipilimumab), novel antibody platforms (e.g., blinatumomab), and oncolytic
viruses (e.g., T‐Vec) (Table
2). For cancer immunotherapies and other medicines that have the potential to demonstrate
substantial improvement over existing therapies for serious illnesses including cancer,
the FDA, EMA, and PMDA have each developed programs to support their expedited clinical
development and approval. These programs include Fast Track Designation, Breakthrough
Designation, Accelerated Approval, and Priority Review through the FDA, Accelerated
Assessment, Conditional Marketing Authorization and Priority Medicines (PRIME) through
the EMA, and SAKIGAKE “pioneer/forerunner” designation through PMDA.
One of the biggest challenges in obtaining expedited regulatory approval of cancer
immunotherapies is the selection of a clinical trial end point that adequately reflects
clinical benefit. While an improvement in OS remains the gold standard clinical trial
end point for regulatory approval, this end point takes significant time to mature,
particularly in the first‐line setting. Thus, surrogate clinical end points that aim
to predict OS have been developed and used to obtain early drug approval without waiting
to reach an OS end point.101, 102 These surrogate end points include PFS, objective
response rate (ORR), and duration of response (DoR). Currently, there is no clear
guidance or consensus on which of these surrogate end points is the best early predictor
of long‐term survival, and it is highly dependent on tumor type. Notably, the accelerated
approvals of both pembrolizumab in PD‐L1+ advanced NCSLC and the combination of nivolumab/ipilimumab
in BRAF wildtype unresectable or metastatic melanoma were granted by the FDA based
on an ORR end point.85, 103 However, for ipilimumab, the improvement in OS would not
have been adequately captured if relying solely on a PFS or ORR end point, since responses
to ipilimumab may be delayed and may even occur after apparent disease progression.104
Traditionally, RECIST or modified WHO criteria are used to evaluate antitumor responses.
However, these criteria were developed for chemotherapies and may not accurately capture
the unique response kinetics of patients treated with immunotherapy, particularly
in cases where durable responses are observed postprogression. Therefore, to better
capture the unique response kinetics of immunotherapies, Wolchock et al. developed
the “Immune‐related Response Criteria” (irRC);48 however, prospective data are required
to determine the value of irRC in predicting OS. While OS is likely to remain the
primary end point for full approval, new (or modified) surrogate end points that accurately
predict OS are needed to facilitate the expedited development of cancer immunotherapies
and combinations.
CONCLUSION
The role of the immune system in combating cancer has been recognized for over a century,
but immunotherapies are only now coming to fruition, with the recent approvals of
the checkpoint inhibitors nivolumab, ipilimumab, and pembrolizumab, the BiTE antibody
construct blinatumomab, the oncolytic virus T‐Vec, and the cancer vaccine sipuleucel‐T.
These approvals have paved the way for combination approaches of immunotherapies with
another immunotherapy, molecularly targeted agents, traditional cytotoxic agents,
and/or radiation therapy, which are expected to revolutionize cancer treatment. Already
the promise of this approach has been realized with the FDA approval of combination
nivolumab and ipilimumab treatment, which leverages the synergistic potential of these
two checkpoint inhibitors to achieve an improved response rate compared with monotherapy.
The success of combination immunotherapy is dependent on our ability to manage development
hurdles including (i) the design of the right preclinical experiments and the translation
of those experiments into the clinic, (ii) optimization of the dose and schedule of
the combination regimen, and (iii) management of the overlapping toxicities that can
be expected based on the mechanism of action of immunotherapies. The application of
quantitative clinical pharmacology approaches in the translational space and throughout
clinical development may help to address these challenges. In addition to these development
hurdles and due to the growing field of cancer immunology, established guidelines
from regulatory agencies to guide immunotherapy development and their combinations
are not yet available. As the field continues to evolve, it is anticipated that the
historical designation of immunotherapies as breakthrough therapies and the limited
development programs required for approval are likely to change as the familiarity
with and availability of immunotherapies grow. However, the likelihood that a more
comprehensive development is needed for regulatory approval may be balanced by a clearer
regulatory strategy for immunotherapies and combination therapies that will likely
emerge as more immunotherapies enter the global market.
Combination immunotherapy is the future of cancer treatment and its success is dependent
on addressing each of these challenges during development in order to provide the
most beneficial treatment to patients.
Conflict of Interest
K.M.M. and C.C.L. are employees of Genentech and stock shareholders of Roche Holding.
A.G., T.Y., Y.Z., and S.K. are employees and stock shareholders of Amgen Inc.
Author Contributions
The first two authors contributed equally to this work. T.Y., K.M., C‐C.L., Y.Z.,
and S.K. wrote the article. ©2016 American Society for Clin. Pharmacol. Ther.